A team of uOttawa Faculty of Medicine researchers have developed a path to a biomanufacturing process that could potentially transform how Canada generates immunotherapeutic materials—specifically natural killer cells and extracellular vesicles (EVs)—to fuel tomorrow's novel cancer treatments.